PENG Block & PENG PRF (PENG-PRF)

March 15, 2026 updated by: Ülkü Sabuncu, Ankara City Hospital Bilkent

Evaluation of the Clinical Effectiveness of Pericapsular Nerve Group (PENG) Block and Pulsed Radiofrequency Applications in Chronic Hip Pain

The primary aim of this study is to prospectively compare the effects of the pericapsular nerve group (PENG) block alone and the combination of PENG block with pulsed radiofrequency (PRF) on pain intensity in patients with chronic hip pain. As a secondary aim, the effects of both treatment modalities on hip function are intended to be evaluated using valid and reliable functional assessment scales. Through this study, it is aimed to demonstrate the clinical contribution of adding PRF to the PENG block and to identify a more effective and longer-lasting approach for the interventional treatment of chronic hip pain.

Study Overview

Status

Recruiting

Detailed Description

Chronic hip pain is a common clinical condition, particularly in the elderly, that significantly impairs quality of life and leads to functional limitation and dependence in daily activities. Chronic hip pain caused by degenerative, inflammatory, and mechanical conditions-most notably hip osteoarthritis-often remains inadequately controlled despite medical treatment, physical therapy, and rehabilitation. Although surgical interventions can be effective, they are not suitable for all patients due to advanced age, comorbidities, or surgical contraindications. Therefore, minimally invasive interventional pain management techniques have gained increasing importance in the treatment of chronic hip pain.

The nociceptive innervation of the hip joint primarily arises from the anterior capsule, which is mainly supplied by the sensory branches of the femoral, obturator, and accessory obturator nerves. Based on this anatomical rationale, the pericapsular nerve group (PENG) block is an ultrasound-guided technique that targets these sensory fibers to provide effective analgesia without causing motor blockade. Previous studies have shown that the PENG block reduces pain scores and improves functional mobility in both acute and chronic hip pain; however, its analgesic effect may be time-limited, requiring repeated applications in some patients.

Pulsed radiofrequency (PRF), unlike conventional thermal radiofrequency, aims to modulate nerve transmission without causing tissue destruction and may provide longer-lasting analgesia through neuromodulatory mechanisms. Recent evidence suggests that combining PRF with peripheral nerve blocks may prolong analgesic effects compared with nerve blocks alone. However, prospective studies directly comparing PENG block alone with PENG block combined with PRF in chronic hip pain are limited, highlighting the need for further investigation.

Study Type

Observational

Enrollment (Estimated)

84

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Ankara, Turkey (Türkiye), 06680
        • Recruiting
        • Ankara Bilkent City Hospital
        • Contact:
          • Ulku Sabuncu Assoc. Prof.
          • Phone Number: 905337085212

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

18-80 years old with chronical hip pain

Description

Inclusion Criteria:

  • Presence of chronic hip pain lasting at least 3 months
  • Baseline Visual Analog Scale (VAS) score ≥ 4
  • Clinical and/or radiological diagnosis of hip osteoarthritis
  • Inadequate response to conservative treatments

Exclusion Criteria:

  • Local or systemic infection at the intervention site
  • Coagulopathy or inability to discontinue anticoagulant therapy
  • Hip pain related to malignancy
  • History of previous hip arthroplasty
  • Severe neurological deficit
  • Pregnancy or breastfeeding

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Group PENG
The initial step in patients diagnosed with chronic hip pain is a diagnostic intervention, namely the application of a pericapsular nerve group (PENG) block. In patients who benefit from the diagnostic block-defined as a reduction of 50% or more in VAS scores following the procedure-pulsed radiofrequency (PRF) treatment is added as a second-stage intervention. This stepwise approach reflects standard clinical practice, and both procedures are commonly used in clinical praqctice for the management of chronic hip pain. However, the available evidence in the literature on this approach is largely limited to case reports and retrospective case series. The aim of the present study is to document and share the clinical outcomes of this treatment strategy routinely applied in clinical practice.

This intervention consists of a stepwise, two-stage treatment protocol routinely applied in our clinical practice for the management of chronic hip pain. In the first stage, all patients undergo an ultrasound-guided pericapsular nerve group (PENG) block as a diagnostic and therapeutic procedure. Pain intensity is assessed using the Visual Analog Scale (VAS) following the diagnostic block. Only patients who demonstrate a clinically meaningful response, defined as a reduction of 50% or greater in VAS scores, proceed to the second stage of the intervention.

In the second stage, pulsed radiofrequency (PRF) treatment is applied to the same target region in addition to the PENG block, aiming to achieve longer-lasting analgesia through neuromodulation without tissue destruction.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in pain intensity measured by the Visual Analog Scale (VAS, 0-10; higher scores indicate worse pain)
Time Frame: baseline (pre-procedure) and at 1 week, 1 month, 3 months, and 6 months after the procedure.
Pain intensity will be assessed using the Visual Analog Scale (VAS), a validated pain measurement tool ranging from 0 to 10, where 0 indicates no pain and 10 represents the worst pain imaginable.
baseline (pre-procedure) and at 1 week, 1 month, 3 months, and 6 months after the procedure.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Pain, Stiffness, and Physical Function Measured by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC, 0-96)
Time Frame: baseline (pre-procedure) and at 1 week, 1 month, 3 months, and 6 months after the procedure.

Pain, stiffness, and physical function were assessed using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC; total score range 0-96, with higher scores indicating worse symptoms and functional limitation). The change in WOMAC total score from baseline to 1 month following pulsed radiofrequency (PRF) treatment was evaluated as a secondary outcome.

Additional analyses included changes in WOMAC subscale scores (pain, stiffness, and physical function) at 1 week, 3 months, and 6 months post-intervention. A clinically meaningful improvement was defined as a ≥20% reduction in the total WOMAC score compared with baseline.

baseline (pre-procedure) and at 1 week, 1 month, 3 months, and 6 months after the procedure.
Change in Hip Function Measured by the Harris Hip Score (HHS, 0-100)
Time Frame: Baseline (pre-procedure), 1 week, 1 month (primary functional endpoint), 3 months, and 6 months after pulsed radiofrequency (PRF) treatment.

Hip pain and functional status were evaluated using the Harris Hip Score (HHS; total score range 0-100, with higher scores indicating better hip function). The HHS assesses four domains: pain, function (activities of daily living and gait), absence of deformity, and range of motion.

The change in total HHS from baseline to 1 month after pulsed radiofrequency (PRF) treatment was analyzed as a secondary outcome. Additional assessments were performed at 1 week, 3 months, and 6 months post-intervention to evaluate the sustainability of functional improvement.

A clinically meaningful improvement was defined as an increase of ≥10 points in the total HHS compared with baseline.

Baseline (pre-procedure), 1 week, 1 month (primary functional endpoint), 3 months, and 6 months after pulsed radiofrequency (PRF) treatment.
Secondary Outcome: TAnalgesic Use
Time Frame: Baseline and at 1 week, 1 month, 3 months, and 6 months post-intervention

The following parameters were evaluated as secondary outcomes:

Analgesic consumption: Changes in daily analgesic dose and frequency of use were recorded and compared between baseline and post-intervention follow-up visits.

Baseline and at 1 week, 1 month, 3 months, and 6 months post-intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

  • Jadon A. Pulsed Radiofrequency (PRF) of Pericapsular Nerves Group (PENG) in Chronic Hip Pain-A Case Report. Turk J Anaesthesiol Reanim. 2021 Dec;49(6):490-493. doi: 10.5152/TJAR.2021.1080. PMID: 35110031; PMCID: PMC9472694.
  • 10.5152/TJAR.2021.21230

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 1, 2026

Primary Completion (Estimated)

February 1, 2027

Study Completion (Estimated)

February 28, 2027

Study Registration Dates

First Submitted

January 14, 2026

First Submitted That Met QC Criteria

January 14, 2026

First Posted (Actual)

January 22, 2026

Study Record Updates

Last Update Posted (Actual)

March 18, 2026

Last Update Submitted That Met QC Criteria

March 15, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Osteoarthritis (OA) of the Hip

Clinical Trials on PENG Block Pulsed radiofrequency

Subscribe